Clinical trials of VEGF receptor tyrosine kinase inhibitors in pancreatic cancer.

@article{Cabebe2007ClinicalTO,
  title={Clinical trials of VEGF receptor tyrosine kinase inhibitors in pancreatic cancer.},
  author={Elwyn C. Cabebe and G. A. Fisher},
  journal={Expert opinion on investigational drugs},
  year={2007},
  volume={16 4},
  pages={467-76}
}
Pancreatic cancer is the fourth leading cause of cancer-related deaths in Western countries and is among the deadliest diseases in humans. At present, gemcitabine is the standard chemotherapy for advanced pancreatic cancer, although (despite its use) prognosis continues to be dismal with a median survival of < 6 months. While targeting tumor vasculature has provided improved outcomes in colon, lung, breast and renal cell cancers, trials of angiogenesis inhibitors have lagged behind in… CONTINUE READING

Citations

Publications citing this paper.
Showing 1-10 of 13 extracted citations

Similar Papers

Loading similar papers…